Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Afatinib is an approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations.
• Stevens-Johnson syndrome (SJS) is a rare but severe adverse event associated with EGFR-directed TKIs.

Observation:

• A case report details a 79-year-old female with metastatic EGFR-mutated NSCLC who developed SJS after two months of first-line afatinib treatment.
• The patient presented with severe cutaneous adverse drug reactions involving skin and mucous membranes.

Findings:

• Discontinuation of afatinib was initiated upon SJS diagnosis.
• Systemic glucocorticoid therapy was administered concurrently with afatinib cessation.

Implications:

• This case highlights the importance of recognizing SJS as a potential adverse reaction to afatinib in NSCLC patients.
• Prompt identification and appropriate management, including TKI discontinuation and glucocorticoid use, are crucial for patient recovery and improved outcomes.